Published in Clinical Trials Week, October 20th, 2008
"The randomized Phase 2 study of sapacitabine in patients with elderly AML and myelodysplastic syndromes (MDS) achieved its enrollment target of the AML stratum in accordance with the protocol approximately three months ahead of forecast," said Dr. Judy Chiao, M.D., Vice President, Clinical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.